The FDA has approved a new HIV medication called Biktarvy. It is a single pill taken once a day. Biktarvy treats HIV-1 infection in adults and children who weigh at least 14 kg (about 31 pounds). It combines three drugs: bictegravir, emtricitabine, and tenofovir alafenamide. These drugs work together to lower the amount of HIV in the body and keep it under control.
Biktarvy is for two groups of people. The first group is people who have never taken HIV medicine before. The second group is people who already have very low levels of HIV (less than 50 copies per mL) and are on a stable treatment plan. These patients must not have resistance to bictegravir or tenofovir. The approval gives doctors a new option for a broad range of patients, including children.
This approval is good news for many people living with HIV. It offers a simple, once-daily treatment that can help control the virus. However, Biktarvy is not for everyone. It is not recommended for people with severe kidney problems or severe liver problems. It is also not a cure for HIV.
If you or a loved one has HIV, talk to your doctor about whether Biktarvy might be a good option. Your doctor can help you understand the benefits and risks based on your health history. Always follow your doctor's advice about HIV treatment.